AxoGen Q1 revenue beats analyst estimates

AxoGen

28/04/2026 12:13

Overview

US nerve repair solutions provider's Q1 revenue grew 27% yr/yr, beating analyst expectations

Adjusted net income for Q1 swung to profit from prior-year loss

Outlook

AxoGen expects 2026 revenue growth of at least 20%, or $270 mln for the full yr

Company forecasts 2026 gross margin in the range of 74% to 76%

AxoGen expects to be free cash flow positive for the full yr 2026

Result Drivers

BROAD-BASED MARKET GROWTH - Co said Q1 revenue growth was broad-based, with double-digit gains in all target markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

COMMERCIAL EXECUTION - Co attributed performance to the relevance of market development strategies and strength of commercial execution

Company press release: ID:nGNX8LnKhG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$61.50 mln
$57.73 mln (9 Analysts)
Q1 Adjusted Net Income
$4.10 mln
Q1 Net Income
-$19.60 mln
Q1 Adjusted EBITDA
$5.70 mln
Q1 Gross Margin
75.20%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for AxoGen Inc is $42.50, about 7.9% above its April 27 closing price of $39.39

The stock recently traded at 74 times the next 12-month earnings vs. a P/E of 68 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)